The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy.
Erika J Schneble
No relevant relationships to disclose
Sonia A. Perez
No relevant relationships to disclose
John S. Berry
No relevant relationships to disclose
Alfred F Trappey
No relevant relationships to disclose
Tim Vreeland
No relevant relationships to disclose
Diane F. Hale
No relevant relationships to disclose
Alan K. Sears
No relevant relationships to disclose
Guy T. Clifton
No relevant relationships to disclose
Eric von Hofe
No relevant relationships to disclose
Alexandros Ardavanis
No relevant relationships to disclose
Nathan M. Shumway
No relevant relationships to disclose
Sathibalan Ponniah
No relevant relationships to disclose
Michael Papamichail
No relevant relationships to disclose
George Earl Peoples
No relevant relationships to disclose
Elizabeth Ann Mittendorf
No relevant relationships to disclose